Scholarlink

Background <p>A uniform consensus on the optimal sequencing of treatment modalities in locally advanced gastric cancer is not reached due to conflicting results worldwide. We conducted a retrospective propensity-matched analysis to compare survival of locally advanced gastric cancer patients who were treated with peri-operative chemotherapy followed by surgery or upfront surgery followed by adjuvant chemotherapy.</p> Methods <p>Deidentified records of prospectively maintained data of locally advanced gastric cancer patients treated from 2015 to 2020 were collected. A 1:1 propensity matching with a tolerance limit of 0.2 was performed. The outcome variables including recurrence-free and overall survival were compared among the matched groups using log-rank tests and Cox proportional hazards analysis was performed.</p> Results <p>Two hundred patients (64 in peri-operative chemotherapy and 136 in the upfront surgery group) were included in the study. Variables including age group, sex, gastric outlet obstruction, tumor site, clinical T stage and node positivity were used for matching. The median overall survival and recurrence-free survival were found to be 21.90&#xa0;months (95% CI = 13.30–30.49) and 15.08&#xa0;months (95% CI = 8.17–21.98), respectively, in the peri-operative chemotherapy arm and 18.70&#xa0;months (95% CI = 11.88–25.51) and 13.49&#xa0;months (95% CI = 6.76–20.21), respectively, in upfront surgery arm with no significant difference (median follow-up 42&#xa0;months). Patients who presented with pallor had Borrmann type 4 on endoscopy, received lesser number of chemotherapy cycles, lymph node ratio was &gt; 0.13 and perineural invasion were associated with worse overall survival and recurrence-free survival.</p> Conclusion <p>In this real-world scenario, retrospective propensity-matched study, no difference was noted in overall survival and recurrence-free survival between patients who received peri-operative chemotherapy or upfront surgery followed by adjuvant chemotherapy in locally advanced gastric cancer.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Perioperative versus adjuvant chemotherapy in carcinoma stomach—A retrospective propensity-matched analysis

  • 期刊论文

  • 发表日期：

    2025年6月18日

查看全文
  • Archana Elangovan,
  • Prasanth Penumadu,
  • Biswajit Dubashi,
  • N Sreekumaran Nair,
  • Balasubramanian A

摘要

Background

A uniform consensus on the optimal sequencing of treatment modalities in locally advanced gastric cancer is not reached due to conflicting results worldwide. We conducted a retrospective propensity-matched analysis to compare survival of locally advanced gastric cancer patients who were treated with peri-operative chemotherapy followed by surgery or upfront surgery followed by adjuvant chemotherapy.

Methods

Deidentified records of prospectively maintained data of locally advanced gastric cancer patients treated from 2015 to 2020 were collected. A 1:1 propensity matching with a tolerance limit of 0.2 was performed. The outcome variables including recurrence-free and overall survival were compared among the matched groups using log-rank tests and Cox proportional hazards analysis was performed.

Results

Two hundred patients (64 in peri-operative chemotherapy and 136 in the upfront surgery group) were included in the study. Variables including age group, sex, gastric outlet obstruction, tumor site, clinical T stage and node positivity were used for matching. The median overall survival and recurrence-free survival were found to be 21.90 months (95% CI = 13.30–30.49) and 15.08 months (95% CI = 8.17–21.98), respectively, in the peri-operative chemotherapy arm and 18.70 months (95% CI = 11.88–25.51) and 13.49 months (95% CI = 6.76–20.21), respectively, in upfront surgery arm with no significant difference (median follow-up 42 months). Patients who presented with pallor had Borrmann type 4 on endoscopy, received lesser number of chemotherapy cycles, lymph node ratio was > 0.13 and perineural invasion were associated with worse overall survival and recurrence-free survival.

Conclusion

In this real-world scenario, retrospective propensity-matched study, no difference was noted in overall survival and recurrence-free survival between patients who received peri-operative chemotherapy or upfront surgery followed by adjuvant chemotherapy in locally advanced gastric cancer.

Graphical Abstract